Dr.Brian qualified as a doctor at Guy’s Hospital Medical School in London in 1980 with a BSc in Pathology and MBBS. After a year in Pathology, he spent the rest of my first 8 years of my career in hospital and emergency medicine obtaining my MRCP in 1984. In 1988, he moved to the University of Manchester to spend six years attached to the Renal Unit conducting clinical research into cyclosporine nephrotoxicity and how this risk can be successfully managed in patients. During that time, Dr.Brian gained experience as a clinical trial investigator and laboratory research into endothelial cells. In 1994, Dr.Brian was awarded a M.D. based on my clinical research and published a dozen or so papers.
Following a short spell on the renal unit in Preston, Dr.Brian moved to the UK regulatory agency which in 1994 was called the Medicines Control Agency where he became a Senior Medical Assessor in the Pharmacovigilance Assessment Group. Brain was the first EU pharmacovigilance assessor in the centralised procedure and the first assessor involved in the Article 12 procedure. Vaccines was part of his portfolio and this involved assessment of the benefits and risks of MMR vaccine something which was personally of great importance to him given that by that time he was the proud Dad of 5 beautiful children !
In 1999, Dr.Brian moved to Parexel International Scientific and Medical Services where he became a Senior Medical Director. During that time, Dr.Brian gained considerable experience of clinical research at all phases and contract qualified person for pharmacovigilance (QPPV) services. In 2005, Dr.Brian moved to Janssen Cilag where he was Deputy Qualified Person for pharmacovigilance for about 18 months before moving to NDA Regulatory Science Ltd. in July 2007 where he is now Principal Consultant in Pharmacovigilance and Drug Safety.
Dr.Brian is passionate about training and education in pharmacovigilance and safe use of medicines and has been involved in several voluntary activities. From 2005 until 2015, Dr.Brian was panel convener monitoring the training of UK pharmaceutical physicians in Drug Safety Surveillance on behalf of the Faculty of Pharmaceutical Medicine.
Through the Drug Information Association, Dr.Brian was a co-chair of the Clinical Safety and Pharmacovigilance SIAC between 2004 and 2008 involved in arranging annual meetings in Washington DC, pharmacovigilance tracks at the Annual Meeting and Clinical Research Forum. Dr.Brian was one of the founding members of the DIA QPPV Forum which started in 2006 and he is still on the organising committee.
Dr.Brian has been an active member of the International Society of Pharmacovigilance since 1999. I am currently Director of ISoP Secretariat Ltd, was Treasurer for 8 years and last year was elected as an Advisory Board Member of ISoP. He has published several original articles proposing systematic reform of pharmaceutical safety.
In a volunteer capacity, Dr.Brian is Vice President Pharmacovigilance & Drug Safety in the Alliance Clinical Research Excellence and Safety (ACRES) where he is leading a team looking at the application of organisational science to the system for optimising use of medicines at all phases of their lifecycle.
In the UK, Dr.Brian is the Chair of UK Pharmaceutical Human Factors & Ergonomics group which is the first initiative of its kind anywhere for placing the human at the centre of system for medicines in the UK & Ireland by applying systems sciences. In addition, Dr.Brian is an ordinary Member of the British Pharmacology Society, TOPRA and the Institute of Clinical Research